Evidence map›Paper›PMID 22439686›Full record

ArticleAccounts of chemical research2012

Charge-reversal lipids, peptide-based lipids, and nucleoside-based lipids for gene delivery.

Caroline M LaManna, Hrvoje Lusic, Michel Camplo, Thomas J McIntosh, Philippe Barthélémy, Mark W Grinstaff

Open access · greenAbstract read
In one paragraph

Article in Accounts of chemical research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Rational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  6. Charge-Conversion Strategies for Nucleic Acid Delivery.Advanced functional materials · 2021
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Tri-peptide cationic lipids for gene delivery.Journal of materials chemistry. B · 2015
    Article
  14. Designer lipids for drug delivery: from heads to tails.Journal of controlled release : official journal of the Controlled Release Society · 2014
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Caroline M LaMannaDepartments of Biomedical Engineering and Chemistry, Boston University, Massachusetts 02215, United States.
Hrvoje Lusic
Michel Camplo
Thomas J McIntosh
Philippe Barthélémy
Mark W Grinstaff
Boston University · USDuke University Hospital · USUniversité de Bordeaux · FR

Funding

TRP and AQP Channels: Modulation of Function, Raft Location by Membrane LipidsR01GM027278 · NIGMS · DUKE UNIVERSITY · PI MC INTOSH, THOMAS J. · 1985 to 2012
$4.6M
Reversing Electrostatic Interactions for Improved Gene DeliveryR01EB005658 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI GRINSTAFF, MARK W. · 2006 to 2009
$1.4M
NIBIB NIH HHS EB005658NIBIB NIH HHS R01 EB005658NIGMS NIH HHS GM27278NIGMS NIH HHS R01 GM027278
6 · The paper itself

Abstract

Twenty years after gene therapy was introduced in the clinic, advances in the technique continue to garner headlines as successes pique the interest of clinicians, researchers, and the public. Gene therapy's appeal stems from its potential to revolutionize modern medical therapeutics by offering solutions to myriad diseases through treatments tailored to a specific individual's genetic code. Both viral and non-viral vectors have been used in the clinic, but the low transfection efficiencies when non-viral vectors are used have lead to an increased focus on engineering new gene delivery vectors. To address the challenges facing non-viral or synthetic vectors, specifically lipid-based carriers, we have focused on three main themes throughout our research: (1) The release of the nucleic acid from the carrier will increase gene transfection. (2) The use of biologically inspired designs, such as DNA binding proteins, to create lipids with peptide-based headgroups will improve delivery. (3) Mimicking the natural binding patterns observed within DNA, by using lipids having a nucleoside headgroup, will produce unique supramolecular assembles with high transfection efficiencies. The results presented in this Account demonstrate that engineering the chemical components of the lipid vectors to enhance nucleic acid binding and release kinetics can improve the cellular uptake and transfection efficacy of nucleic acids. Specifically, our research has shown that the incorporation of a charge-reversal moiety to initiate a shift of the lipid from positive to negative net charge improves transfection. In addition, by varying the composition of the spacer (rigid, flexible, short, long, or aromatic) between the cationic headgroup and the hydrophobic chains, we can tailor lipids to interact with different nucleic acids (DNA, RNA, siRNA) and accordingly affect delivery, uptake outcomes, and transfection efficiency. The introduction of a peptide headgroup into the lipid provides a mechanism to affect the binding of the lipid to the nucleic acid, to influence the supramolecular lipoplex structure, and to enhance gene transfection activity. Lastly, we discuss the in vitro successes that we have had when using lipids possessing a nucleoside headgroup to create unique self-assembled structures and to deliver DNA to cells. In this Account, we state our hypotheses and design elements as well as describe the techniques that we have used in our research to provide readers with the tools to characterize and engineer new vectors.

Indexed as

AnimalsCHO CellsCricetinaeCricetulusDNALipidsNucleosidesPeptidesRNARNA, Small InterferingTransfectionDNALipidsNucleosidesPeptidesRNARNA, Small Interfering

Identifiers

PMID22439686
PMCPMC3878820
OpenAlexW2004149692

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.